Literature DB >> 26554932

Impact of a multidisciplinary approach in enteropathic spondyloarthritis patients.

Paola Conigliaro1, Maria Sole Chimenti1, Marta Ascolani2, Paola Triggianese1, Lucia Novelli1, Sara Onali2, Elisabetta Lolli2, Emma Calabrese2, Carmelina Petruzziello2, Francesco Pallone2, Roberto Perricone3, Livia Biancone2.   

Abstract

Spondyloarthritis (SpA) and inflammatory bowel disease (IBD) are chronic autoinflammatory diseases that partially share the genetic predisposition and the unchecked inflammatory response linking the gut to the joints. The coexistence of both conditions in patients and the increased cross-risk ratios between SpA and IBD strongly suggest a shared pathophysiology. The prevalence of Enteropathic-related Spondyloarthritis (ESpA) in IBD patients shows a wide variation and may be underestimated. It is well accepted that the management of joint pain requires rheumatological expertise in conjunction with gastroenterologist assessment. In this view, we aimed at assessing, in a prospective study performed in a combined Gastro-Intestinal and Rheumatologic "GI-Rhe" clinic: (1) the prevalence of ESpA and other rheumatologic diseases in IBD patients with joint pain; (2) the features of the ESpA population; and (3) the diagnostic delay and the potential impact of the combined assessment. From November 2012 to December 2014, IBD patients with joint pain referring to a dedicated rheumatologist by the IBD-dedicated gastroenterologist were enrolled. Clinical and biochemical evaluations, joint involvement and disease activity assessment, diagnostic delay, and treatment were recorded. IBD patients (n=269) with joint pain were jointly assessed in the "GI-Rhe" Unit. A diagnosis of ESpA was made in 50.5% of IBD patients with joint pain. ESpA patients showed a peripheral involvement in 53% of cases, axial in 20.6% and peripheral and axial in 26.4% of cases. ESpA patients had a higher prevalence of other autoimmune extra-intestinal manifestations and received more anti-TNF treatment compared with IBD patients. A mean diagnostic delay of 5.2 years was revealed in ESpA patients. Patients with joint disease onset in the 2002-2012 decade had reduced diagnostic delay compared with those with onset in the 1980-1990 and 1991-2001 decades. Diagnostic delay was further reduced for patients with joint onset in the last two years in conjunction with the establishment of the GI-Rhe clinic. Multidisciplinary approach improved management of rheumatic disorders in IBD patients allowing a more comprehensive care.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Enteropathic spondyloarthritis; Inflammatory bowel disease; Management; Multidisciplinary approach

Mesh:

Year:  2015        PMID: 26554932     DOI: 10.1016/j.autrev.2015.11.002

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  5 in total

1.  Satisfaction and expectations of patients with inflammatory bowel disease on biologic therapy: a multicenter study.

Authors:  Alessandra Guarini; Silvia Biagini; Antonella Capaldi; Daniela Carretto; Anna De Angelis; Salvatore Iudice; Giuseppina Martino; Barbara Marziali; Roberta Mattiola; Cristina Ongarelli; Francesca Maria Onidi; Manuela Prinzio; Reetha Puthiavettil; Romina Sardi; Elisa Schiavoni; Rita Sinatora; Angelo Zullo
Journal:  Ann Gastroenterol       Date:  2016-10-27

2.  Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.

Authors:  Michele Maria Luchetti; Devis Benfaremo; Francesco Ciccia; Laura Bolognini; Monia Ciferri; Alessia Farinelli; Matteo Rossini; Piergiorgio Mosca; Giovanni Triolo; Armando Gabrielli
Journal:  World J Gastroenterol       Date:  2017-10-21       Impact factor: 5.742

3.  Performance of Two Screening Questionnaires for Inflammatory Arthritis in Patients with Inflammatory Bowel Disease.

Authors:  Rubén Queiro; Sergio Rodríguez-Caminero; Sabino Riestra; Ruth de Francisco; Isabel Pérez-Martínez; Javier Ballina
Journal:  Biomed Res Int       Date:  2018-05-08       Impact factor: 3.411

Review 4.  Multidisciplinary working in the management of axial and peripheral spondyloarthritis.

Authors:  Tania Gudu; Deepak R Jadon
Journal:  Ther Adv Musculoskelet Dis       Date:  2020-12-10       Impact factor: 5.346

5.  Two years follow-up of golimumab treatment in refractory enteropathic spondyloarthritis patients with Crohn disease: A STROBE-compliant study.

Authors:  Paola Conigliaro; Maria Sole Chimenti; Paola Triggianese; Arianna D'Antonio; Giorgia Sena; Norma Alfieri; Livia Biancone; Roberto Perricone
Journal:  Medicine (Baltimore)       Date:  2021-03-26       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.